Novo Nordisk extends research collaboration with UK drug discovery firm
Novo Nordisk and e-therapeutics will use the latter’s genomics technology platform to analyse data from diabetes patients.
Archives for August 5, 2019
Marken adds Japanese courier to global lineup
Marken acquires PCX International in Japan, bolstering its presence locally to provide ‘more expansive’ services to the company’s clinical clients.
Samsung Biologics to produce clinical supply as UCB advances Ph I immunotherapy study
Samsung Biologics and UCB agree to an additional drug substance manufacturing deal to produce an anti-tau candidate currently in Phase I clinical trials to treat progressive supranuclear palsy.
Caprion and HistoGeneX form joint company offering new services, greater global reach
Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.
Javara building ‘highly customized’ partnership with doctor-owned medical practice
Javara teams up with a doctor-owned medical practice to increase access to clinical trials – based on the needs of the patient, rather than the needs of big pharma, says CEO.
Narcan-like drug delivery system approved for emergency treatment
Aptar’s needle-free, emergency powder formulation treatment for patients with diabetes and severe hypoglycemia is the company’s first combination drug delivery device with active packaging.
Zambon’s acquisition creates position to ‘achieve advances’ for respiratory diseases
Zambon acquires Breath Therapeutics for €140m to accelerate the commercialization of treatments for severe respiratory diseases.
FDA issues second Form 483 on Dr Reddy’s India plant
Dr Reddy’s receives a Form 483 with five observations, regarding customer complaints for out-of-specifications results of APIs.
Roche signs over Tamiflu rights to Sanofi, anticipating own product approval
Roche agrees for Sanofi to be responsible for the OTC marketing and distribution of Tamiflu in the US market, as it works on approval for its Xofluza competitor product.
Sanofi ends partnership with Lexicon after trial failure
Sanofi asks to terminate a partnership after disappointing clinical trial results and is accused of breach of contract by Lexicon.